David Fredrickson: Our Largest Single Investment in a Facility to Date
David Fredrickson, Executive Vice-President, Oncology Business at AstraZeneca, shared on LinkedIn:
“I am pleased to share that earlier today, AstraZeneca announced plans to invest $50 billion in the United States by 2030, including a proposed new multi-billion dollar substance manufacturing plant in the Commonwealth of Virginia – our largest single investment in a facility to date.
A special thanks to Glenn Youngkin for the partnership to bring this innovative facility to Virginia. The new facility will apply some of the most cutting-edge technology including AI, automation, and data analytics to optimize production, and further expands our strong presence in the United States, which is home to 19 AstraZeneca R and D, manufacturing and commercial sites and 18,000 AstraZeneca employees country wide.
Collectively, this investment is expected to generate tens of thousands of new, highly skilled jobs across the country aimed at delivering next generation medicines for millions of patients in the United States and across the globe.
US audiences can read more about the announcement here.”
More Posts Featuring AstraZeneca.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023